Lack of clinical utility of serum macrophage migration inhibitory factor (MIF) for monitoring therapy response and estimating prognosis in advanced lung cancer [0.03%]
血液巨噬细胞迁移抑制因子(MIF)不适用于监测晚期肺癌治疗反应和估计预后
Alexander Rupp,Sophie Bahlmann,Nicolai Trimpop et al.
Alexander Rupp et al.
Background: Lung cancer is a major burden to global health and is still among the most frequent and most lethal malignant diseases. Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine involved in a ...
Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150 [0.03%]
联合使用CYFRA 21-1和CA 125可预测IMpower150研究中转移性NSCLC患者总生存期和疾病稳定期患者的预后
Anika Mang,Wei Zou,Vinzent Rolny et al.
Anika Mang et al.
Background: Patients with non-small cell lung cancer (NSCLC) and stable disease (SD) have an unmet clinical need to help guide early treatment adjustments. ...
Comparing modeling strategies combining changes in multiple serum tumor biomarkers for early prediction of immunotherapy non-response in non-small cell lung cancer [0.03%]
联合多种血清肿瘤标志物变化的建模策略早期预测非小细胞肺癌免疫治疗无反应性
Frederik A van Delft,Milou M F Schuurbiers,Mirte Muller et al.
Frederik A van Delft et al.
Background: Patients treated with immune checkpoint inhibitors (ICI) are at risk of adverse events (AEs) even though not all patients will benefit. Serum tumor markers (STMs) are known to reflect tumor activity and might ...
Screening approaches for lung cancer by blood-based biomarkers: Challenges and opportunities [0.03%]
基于血液标志物的肺癌筛查方法：挑战与机遇
Daniel van den Broek,Harry J M Groen
Daniel van den Broek
Lung cancer (LC) is one of the leading causes for cancer-related deaths in the world, accounting for 28% of all cancer deaths in Europe. Screening for lung cancer can enable earlier detection of LC and reduce lung cancer mortality as was de...
Pre-analytical stability of the CEA, CYFRA 21.1, NSE, CA125 and HE4 tumor markers [0.03%]
CEA、CYFRA 21.1、NSE、CA125 和 HE4 肿瘤标志物的前分析稳定性
Esra Canki,Milou Mf Schuurbiers,Theodora C Linders et al.
Esra Canki et al.
Background: For lung cancer, circulating tumor markers (TM) are available to guide clinical treatment decisions. To ensure adequate accuracy, pre-analytical instabilities need to be known and addressed in the pre-analytic...
Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction [0.03%]
循环肿瘤DNA（ctDNA）作为肺癌生物标志物：早期检测、监测及预测治疗效果
Michael J Duffy
Michael J Duffy
Circulating tumor DNA (ctDNA), i.e., DNA shed from tumor cells into the bloodstream, is emerging as one of the most useful plasma biomarkers in patients with multiple types of cancer, including patients with non-small cell lung cancer (NSCL...
Blood platelet RNA profiles do not enable for nivolumab response prediction at baseline in patients with non-small cell lung cancer [0.03%]
基线血小板RNA谱不能用于预测非小细胞肺癌患者对纳武单抗的反应
Mirte Muller,Myron G Best,Vincent van der Noort et al.
Mirte Muller et al.
Background: Anti-PD-(L)1 immunotherapy has emerged as a promising treatment approach for non-small cell lung cancer (NSCLC), though the response rates remain low. Pre-treatment response prediction may improve patient allo...
Serum tumor markers for response prediction and monitoring of advanced lung cancer: A review focusing on immunotherapy and targeted therapies [0.03%]
用于预测和监测晚期肺癌免疫治疗和靶向治疗反应的血清肿瘤标志物：综述
Michel van den Heuvel,Stefan Holdenrieder,Milou Schuurbiers et al.
Michel van den Heuvel et al.
Background: The value of serum tumor markers (STMs) in the current therapeutic landscape of lung cancer is unclear. Objective: This sco...